X4 Pharmaceuticals (XFOR) EBT Margin (2018 - 2026)
X4 Pharmaceuticals' (XFOR) quarterly EBT Margin came in at 183.45% in Q2 2026, up 111933.0% on a YoY basis from N/an in Q2 2025, and up 75.46% quarter-over-quarter from 747.45% in Q1 2026.
Powered by 
Analysis
X4 Pharmaceuticals (XFOR) EBT Margin (2018 - 2026) Analysis & Trends
X4 Pharmaceuticals (XFOR) has reported EBT Margin for 5 consecutive years, with 183.45% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EBT Margin rose 111933.0% year-over-year to 183.45%; the trailing twelve-month figure through Jun 2026 stood at 568.98% (down 25888.0% YoY), and the FY2025 full-year result was 225.44%, up 122705.0% from the prior year.
- EBT Margin grew to 183.45% in Q2 2026 per XFOR's latest filing, from 747.45% in the prior quarter.
- Across five years, EBT Margin topped out at 16136.94% in Q2 2024 and bottomed at 6550.18% in Q3 2024.
- Historically, EBT Margin has averaged 219.18% across 3 years, with a median of 931.66% in 2025.
- The widest YoY moves for EBT Margin: up 485924 bps in 2025, down 1743973 bps in 2025.
- Over 3 years, EBT Margin stood at 2758.93% in 2024, then surged by 66 bps to 931.66% in 2025, then soared by 80 bps to 183.45% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 183.45%, 747.45%, and 931.66% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 26.66% |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | 25.18% |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | -4.11% |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | 29.63% |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | -4.34% |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | 12.17% |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn | 18.33% |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | 44.89% |
| 10 | X4 Pharmaceuticals | 510.43 Mn | 315.33 Mn | 7.19 Mn | -183.45% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -183.45% |
| Mar 31, 2026 | -747.45% |
| Dec 31, 2025 | -931.66% |
| Sep 30, 2025 | -1,690.93% |
| Jun 30, 2025 | -1,302.79% |
| Mar 31, 2025 | 1.10% |
| Dec 31, 2024 | -2,758.93% |
| Sep 30, 2024 | -6,550.18% |
| Jun 30, 2024 | 16,136.94% |
| Mar 31, 2020 | -366.33% |
| Dec 31, 2018 | -235.46% |